- The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of AbbVie's (NYSE:ABBV) JAK inhibitor RINVOQ (upadacitinib), as monotherapy or with methotrexate, for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis who have not responded adequately to or are intolerant of one or more disease-modifying anti-rheumatic drugs (DMARDs).
- A final decision from the European Commission usually takes ~60 days.
- Shares up 1% premarket on light volume.